Financial PerformanceStrong balance sheet (~$2B in cash/equivalents) and near-term Casgevy revenues offer strong support towards navigating macro headwinds.
Pipeline DevelopmentPipeline programs are progressing with CTX112 near-term readouts in Oncology/SLE providing additional upside potential.
Product LaunchCasgevy is currently approved in the U.S., Great Britain, the EU, the Kingdom of Saudi Arabia, and the Kingdom of Bahrain for the treatment of both sickle cell disease and transfusion-dependent β-thalassemia, and launches are ongoing.